+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Parkinson's Disease - US Market Insight, Epidemiology and Market Forecast - 2030

  • ID: 4401843
  • Report
  • July 2021
  • Region: United States
  • 248 Pages
  • DelveInsight
Covers the Therapeutics Market Revenue, Treatment Practice/Algorithm and Forecasted Market Size of Parkinson's Disease (PD) from 2017 to 2025 Segmented by Seven Major Markets

FEATURED COMPANIES

  • AbbVie
  • Alkahest/Grifols
  • Athira Pharma
  • Eli Lilly and Company
  • Neuraly
  • Sunovion Pharmaceuticals
  • MORE
This ‘Parkinson's disease (PD)- Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Parkinson's disease in the United States.

The Parkinson's disease market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Parkinson's disease market Size from 2018 to 2030 in the United States market. The report also covers the current Parkinson's disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Study Period: 2018-2030

Parkinson's disease: Disease Understanding and Treatment Algorithm


Parkinson's disease Overview


American Association of Neurological Surgeons defines Parkinson's disease as a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine. Normally, dopamine operates in a delicate balance with other neurotransmitters to help coordinate the millions of nerve and muscle cells involved in the movement. Without enough dopamine, this balance is disrupted, resulting in tremor (trembling in the hands, arms, legs, and jaw), rigidity (stiffness of the limbs), slowness of movement, and impaired balance and coordination are hallmark symptoms of Parkinson's disease. People with Parkinson's also lose the nerve endings that produce norepinephrine, the main chemical messenger of the sympathetic nervous system, which controls many automatic functions of the body, such as heart rate and blood pressure. The loss of norepinephrine might help explain some of the nonmovement features of Parkinson's, such as fatigue, irregular blood pressure, decreased movement of food through the digestive tract, and sudden drop in blood pressure when a person stands up from a sitting or lying-down position.

Parkinson's symptoms usually begin gradually and get worse over time. As the disease progresses, people may have difficulty walking and talking. They may also have mental and behavioral changes, sleep problems, depression, memory difficulties, and fatigue. According to the National Institute on Aging, Parkinson's disease affects both men and women. However, the disease affects about 50% more men than women.

Symptoms of Parkinson's and the rate of progression differ among individuals. Sometimes people dismiss early symptoms of Parkinson's like the effects of normal aging. In most cases, there are no medical tests to definitively detect the disease, so it can be difficult to diagnose accurately. Early symptoms of Parkinson's disease are subtle and occur gradually. For example, affected people may feel mild tremors or have difficulty getting out of a chair. They may notice that they speak too softly or that their handwriting is slow and looks cramped or small. People with Parkinson's often develop a parkinsonian gait that includes a tendency to lean forward, small quick steps as if hurrying forward, and reduced swinging of the arms. They also may have trouble initiating or continuing movement. Studies have shown that symptoms of Parkinson's develop in patients with an 80% or greater loss of dopamine-producing cells in the substantia nigra. As per National Health Services, around one in 500 people are affected by Parkinson's disease. Most people with Parkinson's start to develop symptoms when they're over 50, although around one in 20 people with the condition first experience symptoms when they're under 40.

The exact cause of Parkinson's is unknown. It may have both genetic and environmental components. Low levels of dopamine and norepinephrine, a substance that regulates dopamine, have been linked with Parkinson's. Abnormal proteins called Lewy bodies have also been found in the brains of people with Parkinson's. While there is no known cause, research has identified groups of people who are more likely to develop the condition.

These include:

  • Sex: Men are one and a half times more likely to get Parkinson's than women.
  • Race: Whites are more likely to get Parkinson's than African Americans or Asians.
  • Age: Parkinson's usually appears between the ages of 50 and 60. It only occurs before the age of 40 in 5-10% of cases.
  • Family history: People who have close family members with Parkinson's disease are more likely to develop Parkinson's disease, too.
  • Toxins: Exposure to certain toxins may increase the risk of Parkinson's disease.
  • Head injury: People who experience head injuries may be more likely to develop Parkinson's disease.

Because Parkinson's disease develops over time, various stages help identify how symptoms have progressed and what should be expected next. Generally, there are five stages of Parkinson's disease:

  • Stage I
  • Stage II
  • Stage III
  • Stage IV
  • Stage V
Although there is currently no cure for Parkinson's disease, and treatments are available to help reduce the main symptoms and maintain quality of life for as long as possible. A variety of medicines sometimes help symptoms dramatically. Surgery and deep brain stimulation (DBS) can help in severe cases. With DBS, electrodes are surgically implanted in the brain. They send electrical pulses to stimulate the parts of the brain that control movement.

Parkinson's disease Diagnosis and Treatment


It covers the details of conventional and current medical therapies and diagnosis available in the Parkinson's disease market to treat the condition. It also provides the treatment guidelines and algorithms for the United States.

The Parkinson's disease market report gives a thorough understanding of Parkinson's disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.

Parkinson's disease Epidemiology


The Parkinson's disease epidemiology division provides insights into the historical and current patient pool along with the forecasted trend for the United States. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings


The disease epidemiology covered in the report provides historical and forecasted Parkinson's disease epidemiology segmented as the Total Prevalent Cases of Parkinson's disease, Gender-specific Cases of Parkinson's disease, Severity-specific Prevalence of Parkinson's disease, Age-specific Cases of Parkinson's disease, and Prevalent Cases of Parkinson's Disease based on the onset. The report includes the prevalent scenario of Parkinson's disease symptoms in the United States from 2018 to 2030.

United States Parkinson's disease Epidemiology


The epidemiology segment also provides Parkinson's disease epidemiology data and findings across the United States.

The total prevalent population of Parkinson's disease in the United States was estimated to be 1,073,894 cases in 2020.

Parkinson's disease (PD) Drug Chapters


The drug chapter segment of the Parkinson's disease report encloses the detailed analysis of Parkinson's disease marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps to understand Parkinson's disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Since 2014, the US FDA has approved many new Parkinson's therapies. This momentum is unparalleled in the history of Parkinson's drug development and a promising sign of biopharmaceutical companies' are increasing interest and investment in this field.

Parkinson's disease Emerging Drugs


Mesdopetam/IRL790 (Integrative Research Laboratories AB) acts by antagonizing the dopamine D3 receptor and thereby counteracting the physiological effects of the signal substance dopamine. The dopamine D3 receptor is genetically linked to increased risk of involuntary movements, and patients with PD-levodopa-induced dyskinesia (LID) have higher amounts of D3 receptors in parts of the brain essential for the control of movements. Mesdopetam has successfully gone through clinical studies demonstrating a good safety and tolerability profile. In 2019, a 28-Day Phase IIa study was concluded evaluating the effect and tolerability of mesdopetam in PD patients exhibiting LIDs. The study results show clinically meaningful and quantitatively impressive effects on dyskinesias as assessed by two of the most used measurements in the field: standardized patient-reported diaries (Hauser diaries) and the Unified Parkinson's Disease Rating Scale (UPDRS). Patients reported marked improvements without added side effects, demonstrating mesdopetam's ability to offer a significant qualitative shift in patients' everyday life.

A larger and longer Phase IIb/III study to further evaluate the effects of mesdopetam in PD-LIDs started in November 2020. The clinical Phase IIb/III study with mesdopetam is a randomized, double-blind, and placebo-controlled study to evaluate the effect of mesdopetam in patients with PD affected by troublesome dyskinesias. Top-line results are expected during the first half of 2022
IPX203 (Amneal Pharmaceuticals) is an investigational extended-release oral capsule formulation of carbidopa and levodopa, being studied as a potential treatment for the symptoms of advanced Parkinson's disease. It is designed to have an onset of effect similar to IR CD-LD while providing a longer effect than other oral levodopa products available. The drug is presently being evaluated in two Phase III studies in PD patients.

Parkinson's disease Market Outlook


The Parkinson's disease market outlook builds a detailed comprehension of the historical, current, and forecasted Parkinson's disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Parkinson's disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to clearly view the market at first sight.

According to the publisher, Parkinson's disease market in the United States is expected to change in the study period 2018-2030.

There are currently no disease-modifying treatments for PD, and management predominantly consists of dopaminergic drugs. The most commonly used of these are preparations of levodopa, the precursor of dopamine, which is administered in combination with a dopa-decarboxylase inhibitor, limiting some of the side effects, such as nausea. Dopamine agonists, such as ropinirole or rotigotine, are also used. Monoamine oxidase B inhibitors, such as rasagiline and selegiline, and catechol-O-methyltransferase (COMT) inhibitors such as entacapone, can be used to reduce the metabolism of endogenous dopamine. These treatments can restore dopaminergic activity in the striatum, heralding improvements in the motor features of PD. However, they do not treat many nonmotor features, which are particularly disabling for many patients. Indeed, in some cases, treatments may exacerbate some of the nonmotor symptoms, such as postural hypotension and neuropsychiatric problems.

Key Findings


This section includes a glimpse of the Parkinson's disease market in the US. The market size of Parkinson's disease in the United States markets was USD 1390.1 million in 2020.

The United States: Market Outlook


This section provides the total Parkinson's disease market size, market size of Parkinson's disease by systemic therapies (class-wise), and market size of Parkinson's disease by-product in the United States.

The approved medication therapies are categorized into seven groups that include levodopa, carbidopa-levodopa infusion (Duodopa), dopamine agonists (Mirapex, Requip, Neupro), MAO B inhibitors (Zelapar, Azilect, Xadago), catechol o-methyltransferase (COMT) inhibitors (Tasmar, Comtan), anticholinergics (Cogentin, Artane), adenosine A2a antagonists (Istradefylline) and amantadine (Gocovri, OSMOLEX ER). The treatment is given based on the stages of the disease, symptoms shown, and those who are already receiving some medication. Based on the mentioned criteria the treatment can be classified into early-stage, late-stage, and nonmotor symptoms.

Neurocrine's oral compound Ongentys (opicapone) - approved by the FDA in April 2020 - and Sunovion's thin-film formulation of apomorphine (approved in May 2020) help control symptoms during “off” times, when the gold standard medication levodopa (Sinemet) fails, and Parkinson's symptoms relapses each day. Apomorphine can quickly relieve symptoms when levodopa wears off but must be delivered via injection. However, Sunovion has developed a new delivery method and option for those who prefer it over an injection approach - Kynmobi, a thin-film formulation that can be placed under the tongue.

The crop of recently approved treatments includes other medications (e.g., inhaled levodopa [Inbrija] and istradefylline [Nourianz]) to ease “off” time along with treatments for psychosis, excessive salivation/drooling, and sudden drops in blood pressure. These therapies for nonmovement aspects of Parkinson's are filling longstanding gaps in care and helping patients live better with Parkinson's.

Parkinson's disease Drugs Uptake


This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018-2030. The analysis covers Parkinson's disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Parkinson's disease Pipeline Development Activities


The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses Parkinson's disease key players involved in developing targeted therapeutics.

Major players include Addex Pharma, Annovis Bio Inc, Pharma Two B Ltd, AbbVie, Prevail Therapeutics, Axovant Gene Therapies, Denali Therapeutics, Neurocrine Biosciences, and others, whose key products are expected to get launched in the US market by 20XX.


Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Parkinson's disease emerging therapies.

KOL Views


To keep up with current market trends, we take KOLs and SME's opinions working in the Parkinson's disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Parkinson's disease market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis


The publisher performs a Competitive and Market Intelligence analysis of the Parkinson's disease market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Parkinson's disease, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Parkinson's disease epidemiology and treatment in the United States.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Parkinson's disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Parkinson's disease market; historical and forecasted, is included in the report, covering drug outreach in the United States.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Parkinson's disease market.

Report Highlights

  • In the coming years, the Parkinson's disease market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Parkinson's disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Parkinson's disease. The launch of emerging therapies will significantly impact the Parkinson's disease market
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Parkinson's disease.
  • The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Parkinson's disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Parkinson's disease Pipeline Analysis
  • Parkinson's disease Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Parkinson's disease Report Key Strengths

  • 10-years Forecast
  • The United States Coverage
  • Parkinson's disease Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Parkinson's disease Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions Answered


Market Insights:

  • What was the Parkinson's disease Market share (%) distribution in 2018, and how would it look like in 2030?
  • What would be the Parkinson's disease total market size and market size by therapies in the United States during the forecast period (2018-2030)?
  • What are the key findings pertaining to the market across the United States during the forecast period (2018-2030)?
  • At what CAGR, the Parkinson's disease market is expected to grow in the United States during the forecast period (2018-2030)?
  • What would be the Parkinson's disease market outlook across the United States during the forecast period (2018-2030)?
  • What would be the Parkinson's disease market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Parkinson's disease?
  • What is the historical Parkinson's disease patient pool in the United States?
  • What would be the forecasted patient pool of Parkinson's disease in the United States?
  • What will be the growth opportunities in the United States with respect to the patient population pertaining to Parkinson's disease?
  • At what CAGR the population is expected to grow in the United States during the forecast period (2018-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Parkinson's disease?
  • What are the current treatment guidelines for treating Parkinson's disease in the United States?
  • What are the Parkinson's disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Parkinson's disease?
  • How many therapies are developed by each company for the treatment of Parkinson's disease?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Parkinson's disease?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to Parkinson's disease therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Parkinson's disease and its status?
  • What are the key designations that have been granted for the emerging therapies for Parkinson's disease?
  • What are the global historical and forecasted markets for Parkinson's disease?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Parkinson's disease market
  • To understand the future market competition in the Parkinson's disease market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Parkinson's disease in the United States.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Parkinson's disease market.
  • To understand the future market competition in the Parkinson's disease market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • Alkahest/Grifols
  • Athira Pharma
  • Eli Lilly and Company
  • Neuraly
  • Sunovion Pharmaceuticals
  • MORE
1. Key Insights

2. Report Introduction

3. Executive Summary of Parkinson's disease

4. Disease Background and Overview
4.1. Introduction
4.2. Cause of Parkinson's disease
4.3. Signs and Symptoms of Parkinson's disease
4.3.1. Motor Symptoms
4.3.2. Nonmotor Symptoms
4.3.3. Physical symptoms
4.3.4. Cognitive and psychiatric symptoms
4.4. Stages of Parkinson's disease
4.5. Risk Factors for Parkinson's disease
4.5.1. Gender
4.5.2. Age
4.5.3. Ethnicity
4.5.4. Family History and Genetics
4.5.5. Head Trauma
4.5.6. Environmental Pesticides
4.6. Classification of Parkinson's disease
4.6.1. Juvenile Parkinson Disease
4.6.2. Young-onset Parkinson's disease
4.6.3. Idiopathic Parkinson Disease or Classic Parkinson Disease
4.7. Genetics of Parkinson's disease
4.7.1. Autosomal dominant Parkinson's disease genes
4.7.2. Autosomal recessive Parkinson's disease genes
4.7.3. Autosomal recessive genes causing Parkinsonism with atypical features
4.7.4. Autosomal dominant genes and loci with unclear pathogenicity
4.8. Pathophysiology
4.8.1. The Role of Dopamine
4.8.2. Lewy Bodies and Alpha-Synuclein
4.8.3. Inflammation and Immune Response
4.9. Diagnosis
4.9.1. CT (Computerized Tomography) scan
4.9.2. MRI (Magnetic Resonance Imaging) scan
4.9.3. DaTSCAN-SPECT scan
4.9.4. PET (Positron Emission Tomography) scan
4.9.5. The importance of early diagnosis
4.9.6. Diagnostic Guidelines
4.9.7. Diagnostic Algorithm
4.10. Treatment and Management
4.10.1. Carbidopa-levodopa
4.10.2. Carbidopa-levodopa infusion
4.10.3. Dopamine agonists
4.10.4. Monoamine oxidase B (MAO B) inhibitors
4.10.5. Catechol O-methyltransferase (COMT) inhibitors
4.10.6. Anticholinergics
4.10.7. Amantadine
4.11. Treatment algorithm
4.12. Treatment Guidelines
4.12.1. National Institute for Health and Care Excellence (NICE): Recommendation for Parkinson's disease
4.12.2. EFNS/MDS-ES recommendations on therapeutic management of Parkinson's disease 2010
4.12.3. American Academy of Family Physicians: Recommendations for Treatment of Parkinson's disease
4.12.4. American Academy of Neurology (ANN): Parkinson's disease Quality Measurement Set Update

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Epidemiology of Parkinson's disease
5.3. The United States
5.3.1. Total Prevalent Population of Parkinson's Disease (PD) in the United States
5.3.2. Gender-specific Prevalent Population of Parkinson's Disease (PD) in the United States
5.3.3. Age-specific Prevalent Population of Parkinson's Disease (PD) in the United States
5.3.4. Prevalent Population of Parkinson's Disease (PD) based on Onset in the United States
5.3.5. Stage-specific Prevalence of Parkinson's Disease (PD) in the United States

6. Organizations contributing toward Parkinson's disease

7. Patient Journey

8. Case Reports

9. Marketed Products
9.1. Key cross competition
9.2. KYNMOBI: Sunovion Pharmaceuticals
9.2.1. Product Description
9.2.2. Regulatory Milestone
9.2.3. Other developmental activities
9.2.4. Safety and Efficacy
9.2.5. Side Effects
9.2.6. Product Profile
9.3. Gocovri: Adamas Pharmaceuticals
9.3.1. Product Description
9.3.2. Regulatory Milestone
9.3.3. Other developmental activities
9.3.4. Safety and Efficacy
9.3.5. Side Effects
9.3.6. Product Profile
9.4. Ongentys: Neurocrine Biosciences
9.4.1. Product Description
9.4.2. Regulatory Milestone
9.4.3. Other Developmental Activities
9.4.4. Safety and Efficacy
9.4.5. Side Effects
9.4.6. Product Profile
9.5. OSMOLEX ER: Adamas Pharmaceutical
9.5.1. Product Description
9.5.2. Regulatory Milestone
9.5.3. Other Developmental Activities
9.5.4. Safety and Efficacy
9.5.5. Side Effects
9.5.6. Product Profile
9.6. Xadago: Supernus Pharmaceuticals
9.6.1. Product Description
9.6.2. Regulatory Milestone
9.6.3. Other Development Activities
9.6.4. Safety and Efficacy
9.6.5. Side Effects
9.6.6. Product Profile
9.7. Nourianz: Kyowa Kirin
9.7.1. Product Description
9.7.2. Regulatory Milestone
9.7.3. Safety and Efficacy
9.7.4. Side Effects
9.7.5. Product Profile
9.8. Duopa: AbbVie
9.8.1. Product Description
9.8.2. Regulatory Milestone
9.8.3. Other Developmental Activities
9.8.4. Safety and Efficacy
9.8.5. Side Effects
9.8.6. Product Profile

10. Emerging Therapies
10.1. Key Cross of Emerging Drugs
10.2. Mesdopetam: Integrative Research Laboratories AB
10.2.1. Drug Description
10.2.2. Other development activities
10.2.3. Clinical Development
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. Posiphen: Annovis Bio Inc.
10.3.1. Drug Description
10.3.2. Other Development Activities
10.3.3. Clinical Development
10.3.4. Product Profile
10.4. Tavapadon (CVL-751/PF-06649751): Cerevel Therapeutics
10.4.1. Drug Description
10.4.2. Other Development Activities
10.4.3. Clinical Development
10.4.4. Safety and Efficacy
10.4.5. Product Profile
10.5. IPX203: Amneal Pharmaceuticals
10.5.1. Drug Description
10.5.2. Other Development Activities
10.5.3. Clinical Development
10.5.4. Safety and Efficacy
10.5.5. Product Profile
10.6. P2B001: Pharma Two B
10.6.1. Drug Description
10.6.2. Clinical Development
10.6.3. Safety and Efficacy
10.6.4. Product Profile
10.7. ABBV-951: AbbVie
10.7.1. Drug Description
10.7.2. Other Development Activities
10.7.3. Clinical Development
10.7.4. Safety and Efficacy
10.7.5. Product Profile
10.8. Dipraglurant: Addex Pharma S.A.
10.8.1. Drug Description
10.8.2. Other Development Activities
10.8.3. Clinical Development
10.8.4. Safety and Efficacy
10.8.5. Product Profile
10.9. ND0612: Mitsubishi Tanabe Pharma
10.9.1. Drug Description
10.9.2. Other Development Activities
10.9.3. Clinical Development
10.9.4. Safety and Efficacy
10.9.5. Product Profile
10.10. SPN-830: Supernus Pharmaceuticals
10.10.1. Drug Description
10.10.2. Other Developmental Activities
10.10.3. Clinical Development
10.10.4. Safety and Efficacy
10.10.5. Product Profile
10.11. Other Promising Therapies
10.12. Other Assets in Development
10.13. VY-AADC: Voyager Therapeutics
10.13.1. Drug Description
10.13.2. Other Development Activities
10.13.3. Clinical Development
10.13.4. Product Profile
10.14. Liraglutide: Novo Nordisk
10.14.1. Drug Description
10.14.2. Clinical Development
10.14.3. Product Profile
10.15. NYX-458: Aptinyx
10.15.1. Drug Description
10.15.2. Other Developmental Activities
10.15.3. Clinical Development
10.15.4. Safety and Efficacy
10.15.5. Safety and Efficacy
10.15.6. Product Profile
10.16. SEP-363856: Sunovion/PsychoGenics
10.16.1. Drug Description
10.16.2. Other Development Activities
10.16.3. Clinical Development
10.16.4. Product Profile
10.17. GRF6021: Alkahest/Grifols
10.17.1. Drug Description
10.17.2. Other Developmental Activities
10.17.3. Clinical Development
10.17.4. Safety and Efficacy
10.17.5. Product Profile
10.18. Lenrispodun: Intracellular Therapies
10.18.1. Drug Description
10.18.2. Other Development Activity
10.18.3. Clinical Development
10.18.4. Safety and Efficacy
10.18.5. Product Profile
10.19. PROO1A: Eli Lilly and Company
10.19.1. Drug Description
10.19.2. Other Development Activities
10.19.3. Clinical Development
10.19.4. Product Profile
10.20. Lazucirnon: Alkahest/Grifols
10.20.1. Drug Description
10.20.2. Other development activities
10.20.3. Clinical Development
10.20.4. Product Profile
10.21. ATH-1017: Athira Pharma
10.21.1. Drug Description
10.21.2. Clinical Development
10.21.3. Product Profile
10.22. TAK-071: Takeda
10.22.1. Drug Description
10.22.2. Clinical Development
10.22.3. Product Profile
10.23. AV-101: VistaGen Therapeutics
10.23.1. Drug Description
10.23.2. Other Development activities
10.23.3. Clinical Development
10.23.4. Product Profile
10.24. E2027: Eisai Inc.
10.24.1. Drug Description
10.24.2. Clinical Development
10.24.3. Product Profile
10.25. UCB0599: UCB Biopharma
10.25.1. Drug Description
10.25.2. Other Development Activity
10.25.3. Clinical Development
10.25.4. Safety and Efficacy
10.25.5. Product Profile
10.26. NLY01: Neuraly
10.26.1. Drug Description
10.26.2. Other Developmental Activities
10.26.3. Clinical Development
10.26.4. Safety and Efficacy
10.26.5. Product Profile
10.27. SAGE-718: Sage Therapeutics
10.27.1. Product Description
10.27.2. Clinical Development
10.27.3. Safety and Efficacy
10.27.4. Product Profile
10.28. SCC-138/ K0706: Sun Pharma Advanced Research Company (SPARC)
10.28.1. Product Description
10.28.2. Clinical Development
10.28.3. Product Profile
10.29. Kenterin: Enterin
10.29.1. Drug Description
10.29.2. Clinical Development
10.29.3. Safety and Efficacy
10.29.4. Product Profile
10.30. Prasinezumab: Hoffmann-La Roche/Prothena Biosciences Limited
10.30.1. Drug Description
10.30.2. Other Developmental Activities
10.30.3. Clinical Development
10.30.4. Safety and Efficacy
10.30.5. Product Profile
10.31. THN102: Theranexus
10.31.1. Drug Description
10.31.2. Other Developmental Activities
10.31.3. Clinical Development
10.31.4. Safety and Efficacy
10.31.5. Product Profile
10.32. JM-010/Buspirone/Zolmitriptan: Bukwang Pharmaceutical
10.32.1. Drug Description
10.32.2. Other Developmental Activities
10.32.3. Clinical Development
10.32.4. Product Profile
10.33. CVN424: Cerevance Beta
10.33.1. Drug Description
10.33.2. Other Developmental Activities
10.33.3. Clinical Development
10.33.4. Safety and Efficacy
10.33.5. Product Profile

11. Parkinson's disease: the US Market Analysis
11.1. Key Findings
11.2. Market Outlook
11.3. The United States Market Size
11.3.1. Total Market Size of Parkinson's Disease in The United States
11.3.2. Total Market Size of Parkinson's Disease by Therapies in The United States
11.3.3. Total Market Size of Parkinson's Disease by Approved Therapies in The United States
11.3.4. Total Market Size of Parkinson's Disease by Emerging Therapies in The United States

12. KOL Views

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. Appendix
17.1. Bibliography
17.2. Report Methodology

18. Publisher Capabilities

19. Disclaimer

20. About the Publisher

List of Tables
Table 1: Summary of Parkinson’s Disease, Market, Epidemiology, and Key Events (2018-2030)
Table 2: Signs and Symptoms of Parkinson’s disease
Table 3: Differential Diagnosis of Parkinsonism
Table 4: Formulations and key precautions for first-line drugs to treat Parkinson’s disease
Table 5: Potential benefits and harms of dopamine agonists, levodopa, and MAO B inhibitors
Table 6: Potential benefits and harms of dopamine agonists, levodopa, and MAO B inhibitors
Table 7: Pharmacological management of Non-motor Symptoms
Table 8: Nonpharmacological management of motor and nonmotor symptoms
Table 9: Practical recommendations for the treatment of early untreated PD
Table 10: Practical recommendations for the adjustment of initial therapy in patients without motor complications
Table 11: Practical recommendations for the treatment of early untreated PD
Table 12: Key Recommendations for the treatment of Parkinson’s disease
Table 13: Total Prevalent Population of Parkinson’s Disease (PD) in the United States (2018-2030)
Table 14: Gender-specific Prevalent Population of Parkinson’s Disease (PD) in the United States (2018-2030)
Table 15: Age-specific Prevalent Population of Parkinson’s Disease (PD) in the United States (2018-2030)
Table 16: Prevalent Population of Parkinson’s Disease (PD) based on onset in the United States (2018-2030)
Table 17: Stage-specific Prevalence of Parkinson’s Disease (PD) in the United States (2018-2030)
Table 18: Organizations contributing towards Parkinson’s Disease
Table 19: Key cross of the Marketed drugs
Table 20: Mesdopetam, Clinical Trial Description, 2021
Table 21: Posiphen, Clinical Trial Description, 2021
Table 22: Tavapadon, Clinical Trial Description, 2021
Table 23: IPX203, Clinical Trial Description, 2021
Table 24: PB2001, Clinical Trial Description, 2021
Table 25: ABBV-951, Clinical Trial Description, 2021
Table 26: Dipraglurant, Clinical Trial Description, 2021
Table 27: ND0612, Clinical Trial Description, 2021
Table 44: Apomorphine infusion; Clinical Trial Description, 2021
Table 28: VY-AADC, Clinical Trial Description, 2021
Table 29: Liraglutide, Clinical Trial Description, 2021
Table 30: NYX-458, Clinical Trial Description, 2021
Table 31: SEP-363856, Clinical Trial Description, 2021
Table 32: GRF6021, Clinical Trial Description, 2021
Table 33: Lenrispodun, Clinical Trial Description, 2021
Table 34: PROO1A, Clinical Trial Description, 2021
Table 35: AKST4290, Clinical Trial Description, 2021
Table 36: ATH-1017, Clinical Trial Description, 2021
Table 37: TAK-071, Clinical Trial Description, 2021
Table 38: AV-101, Clinical Trial Description, 2021
Table 39: E2027, Clinical Trial Description, 2021
Table 40: UCB0599, Clinical Trial Description, 2021
Table 41: NLY01, Clinical Trial Description, 2021
Table 42: SAGE-718, Clinical Trial Description, 2021
Table 43: K0706; Clinical Trial Description, 2021
Table 45: Prasinezumab (PRX002/RO7046015/ RG7935); Clinical Trial Description, 2021
Table 46: THN102, Clinical Trial Description, 2021
Table 47: JM-101, Clinical Trial Description, 2021
Table 48: CVN424 Clinical Trial Description, 2021
Table 49: The United States Market Size of Parkinson’s Disease in USD Million (2018-2030)
Table 50: The United States Market Size of Parkinson’s Disease by Therapies in USD Million (2018-2030)
Table 51: The United States Market Size of Parkinson’s Disease by Approved Therapies in USD Million (2018-2030)
Table 52: The United States Market Size of Parkinson’s Disease by Emerging Therapies in USD Million (2018-2030)

List of Figures
Figure 1: Causes of Parkinson’s Disease
Figure 2: Stages of Parkinson’s disease
Figure 3: Causes of Parkinson’s disease
Figure 4: Risk Factors for Parkinson’s Disease
Figure 5: Types of Parkinson Disease
Figure 6: Dopamine level in a normal and Parkinson’s affected neuron
Figure 7: Pathways to Parkinson’s Disease
Figure 8: Queen Square Brain Bank UK PDS Brain Bank Criteria for the diagnosis of PD
Figure 9: Diagnosis and Management of Parkinson’s Disease
Figure 10: Pharmacologic Treatment options available for Parkinson’s disease
Figure 11: Algorithm for medical treatment of Parkinson’s disease
Figure 12: Treatment guidelines for the progressive stages of Parkinson’s disease
Figure 13: Total Prevalent Population of Parkinson’s Disease (PD) in the US (2018-2030)
Figure 14: Gender-specific Prevalent Population of Parkinson’s Disease (PD) in the United States (2018-2030)
Figure 15: Age-specific Prevalent Population of Parkinson’s Disease (PD) in the United States (2018-2030)
Figure 16: Prevalent Population of Parkinson’s Disease (PD) based on onset in the US (2018-2030)
Figure 17: Stage-specific Prevalence of Parkinson’s Disease (PD) in the United States (2018-2030)
Figure 18: Market Size of Parkinson’s Disease in the United States, USD Million (2018-2030)
Figure 19: The United States Market Size of Parkinson’s Disease by Therapies in USD Million
Figure 20: The United States Market Size of Parkinson’s Disease by Approved Therapies in USD Million (2018-2030)
Figure 21: The United States Market Size of Parkinson’s Disease by Emerging Therapies in USD Million (2018-2030)
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Sunovion Pharmaceuticals
  • Adamas Pharmaceuticals
  • Neurocrine Biosciences
  • Adamas Pharmaceutical
  • Supernus Pharmaceuticals
  • Kyowa Kirin
  • AbbVie
  • Integrative Research Laboratories AB
  • Annovis Bio Inc.
  • Cerevel Therapeutics
  • Amneal Pharmaceuticals
  • Pharma Two B
  • AbbVie
  • Addex Pharma S.A.
  • Mitsubishi Tanabe Pharma
  • Supernus Pharmaceuticals
  • Voyager Therapeutics
  • Novo Nordisk
  • Aptinyx
  • Sunovion/PsychoGenics
  • Alkahest/Grifols
  • Intracellular Therapies
  • Eli Lilly and Company
  • Alkahest/Grifols
  • Athira Pharma
  • Takeda
  • VistaGen Therapeutics
  • Eisai Inc.
  • UCB Biopharma
  • Neuraly
  • Sage Therapeutics
  • Sun Pharma Advanced Research Company (SPARC)
  • Enterin
  • Hoffmann-La Roche/Prothena Biosciences Limited
  • Theranexus
  • Bukwang Pharmaceutical
  • Cerevance Beta
Note: Product cover images may vary from those shown
Adroll
adroll